Medistim (MEDI)

[TekBot]

Major shareholder disclosure in Medistim ASA by Danske Bank AS

We hereby declare that Danske Bank Group as of January 5 has bought and decreased the holding in Medistim ASA which leads us to reach below 5% threshold. Total aggregated holding is 909,215.00 corresponding to 4.96 % of the total voting rights. Ownership consist of: Danica Pension corresponding to 0.02%, Danske Invest Engros corresponding to 0.12%, Danske Invest corresponding to 0.44%, Kapitalforeningen Danske Invest Institutional corresponding to 1.15%, Finnish Fund corresponding to 0.32%, SICAV corresponding to 1.67% and Danske Fund Norway corresponding to 1.24%.
…

Vis børsmeldingen

Kilde

[TekBot]

Transfer of shares to CEO

Medistim ASA has transferred 12,000 shares to Medistim CEO Kari E. Krogstad, at
the last traded share price in 2022, of 233.00 NOK per share. This is in
accordance with her compensation agreement with the company, as described in the
…

Vis børsmeldingen

Company’s Annual Report. After the transfer, Kari E. Krogstad holds a total of
75,802 shares in the company and Medistim ASA holds 75,033 own shares.

Kilde

[TekBot]

Major shareholder disclosure in Medistim ASA by Danske Bank AS

We hereby declare that Danske Bank Group as of February 7th reached 5% of threshold in Medistim ASA. Total aggregated holding is 931,595.00 corresponding to 5.08 % of the total voting rights. Ownership consist of: Danica Pension corresponding to 0.02%, Danske Invest Engros corresponding to 0.12%, Danske Invest corresponding to 0.44%, Kapitalforeningen Danske Invest Institutional corresponding to 1.27%, Finnish Fund corresponding to 0.32%, SICAV corresponding to 1.67% and Danske Fund Norway corresponding to 1.24%.
…

Vis børsmeldingen

Kilde

[TekBot]

Fourth quarter results and preliminary financials for 2022 for Medistim ASA

Medistim invites you to a presentation of the fourth quarter results and preliminary financials for 2022 and status for the company. The fourth quarter results and preliminary financials will be presented through a webinar. The webinar takes place Wednesday the 1st of March and will start at 08.00 Norwegian time. The webinar will be available on Medistim website after the presentation. Representatives for the company will be:
Kari Eian Krogstad – CEO
Thomas Jakobsen - CFO To sign up to join the
…

Vis børsmeldingen

webinar please follow the link to register:
Presentation of Medistim's Q4 and preliminary year-end results 2022 - Medistim

Kilde

[TekBot]

Medistim to host a Capital Markets Day on Tuesday 21st of March 2023

(Oslo, 23rd February 2023) Medistim ASA (OSE: MEDI) is a niche market leader within ultrasound technology with headquarters in Oslo, Norway. Medistim develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery. Today, the company announces that they will hold a Capital Markets Day at Grand Hotel, Oslo, on March 21st from 9 am to 11 am. Breakfast will be served from 8:30.

Medistim is proud to announce that one of the world’s leading cardiac surgeons, Professor John D. Puskas of Mount Sinai Health System, New York, is joining us to talk about the past, present, and future of Coronary Artery Bypass (CABG) surgery, the need for innovation and Medistim’s role in this. Dr. Puskas is internationally recognized for his expertise in off-pump CABG and has performed more than 5000 off-pump procedures since 1996. He is a global leader in the development of minimally invasive Hybrid Coronary Revascularization, which combines robotic bypass grafting with catheter-based stents in selected patients. Dr. Puskas was also one of the lead investigators on the REQUEST study, a multicenter, prospective study on the influence of Medistim’s Transit Time Flow Measurement and High Frequency Ultrasound Imaging system in >1000 patients, published in the Journal of Thoracic and Cardiovascular Surgery 2020.
…

Vis børsmeldingen

In addition, we are delighted that Chief Physician in Vascular Surgery, Professor Pirkka Vikatmaa, Helsinki University Hospital, Finland, will enlighten us on the need and future for open vascular surgery procedures, and the importance of quality assessment and surgical guidance during these procedures. Dr. Vikatmaa was previously on the board of the European Society of Vascular Surgery (ESVS) and is currently President of the Finnish Surgical Society.
“We look forward to welcoming current and new shareholders to learn more about the fundamentals in Medistim’s addressable markets, directly from the thought leaders in this space,” says Medistim President and CEO, Kari E. Krogstad. “In addition, we will provide a company update, including some direction for our product innovation. We hope to see you there!”

About Medistim:
Medistim was established in 1984 and has a track record of profitable growth over the past 20 years. The company is a pioneer within its segment and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark, and Norway, in addition to the about 50 distributors in Europe, Asia, Middle East, Africa, Canada and South America. For more information, visit the Medistim home page: www.medistim.com

Please register your participation on the following link:
https://conta.cc/3ExdsWq

For more information, contact:

President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com

Kilde

[TekBot]

FOURTH QUARTER & PRELIMINARY YEAR-END RESULTS 2022

Another record quarter ending at MNOK 141.8 in sales (MNOK 112.7). Full year revenue at MNOK 491.9 (MNOK 427.3) is also a new record, up 15.1 %.

Sales growth is driven by all major geographical regions. Currency neutral sales increase by 21.6 % for the quarter and 11.9 % for the year.
…

Vis børsmeldingen

Currency neutral sales of own products increase 24.6 % for the quarter and 14.0 % for the year.

The Vascular business segment grows at 8.8 % for the quarter and 27.3 % for the year.

The Imaging products grows at 33.5 % for the quarter and 44.0 % for the year.

Operating profit (EBIT) for the quarter ended at MNOK 36.5 (MNOK 19.5), with an EBIT margin of 25.7 % (17.3 %). For the year, EBIT ended at MNOK 141.3 (MNOK 116.3), with an EBIT margin of 28.7 % (27.6 %).

The board suggests a dividend of NOK 4.5 (NOK 3.75) per share to the General meeting, a total dividend payout of MNOK 82.1.

Kilde

[Savepig]

Skal vi tro higher low er satt i medistim?

[h3nk1]

Skrekkelig illikvid denne er da, burde den ikke få omsatt mer enn 1000 aksjer og gått mer enn 5 prosent på rapporten?

[Savepig]

Jepp, sånn har medistim nesten alltid vært. Definitivt en negativ side ved aksjen.

Edit:

Hirr

[TekBot]

Board member purchases shares in Medistim

Board member in Medistim ASA, Lars Rønn, has purchased 1271 shares in Medstim ASA the 6th of March. The average price per share purchased was NOK 236.77. After the purchase Lars Rønn has 2506 Medistim shares.
…

Vis børsmeldingen

Kilde

[Savepig]

Fortsatt bra (Medi)stim

[TekBot]

Major shareholder disclosure in Medistim ASA by Danske Bank AS

Danske Bank Group as of March 15 reached below 5% of threshold in Medistim ASA. Total aggregated holding is 912,826.00 corresponding to 4.98 % of the total voting rights. Ownership consist of: Danica Pension corresponding to 0.02%, Danske Invest Engros corresponding to 0.13%, Danske Invest corresponding to 0.39%, Kapitalforeningen Danske Invest Institutional corresponding to 1.27%, Finnish Fund corresponding to 0.29%, SICAV corresponding to 1.64% and Danske Fund Norway corresponding to 1.24%.
…

Vis børsmeldingen

Kilde

[TekBot]

Medistim Expands Market Coverage in Canada by Going Direct

(Oslo, March 20, 2023) Medistim ASA (OSE: MEDI) is a niche market leader in ultrasound technology with headquarters in Oslo, Norway. The company develops and commercializes medical equipment for use in cardiac, vascular, and transplant surgery. Today, Medistim announce that they will expand their market coverage in Canada by establishing a direct sales operation. This move is part of the company’s ongoing commitment to provide exceptional service to customers as well as fulfilling the company’s global growth strategy.

Medistim already has a strong position in Canada with presence in 15 of Canadas 38 cardiac centers. About 18 000 coronary bypass surgeries are performed in Canada per year, and about 37% are supported with Medistim’s technology. The company is well positioned to continue their growth with local sales representatives who will focus on attracting new customers as well as driving the conversion from devices with Transit Time Flow Measurement (TTFM) technology only, to devices combining TTFM and High Frequency Ultrasound (HFUS). In addition, the market within Vascular surgery provides further opportunities for growth.
…

Vis børsmeldingen

“We are excited to announce this strategic move that will strengthen our relationship with our customers in Canada and grow our business there,” says Medistim President and CEO Kari E. Krogstad. “We have had great success in the US with our direct sales force, and the Canadian team will have support from the US Management in their daily operations. We are currently in a transition period with our current distributor Medtronic, which will end on the 30th of April.”

The new subsidiary, Medistim Canada Inc., is a Canadian corporation fully owned by Medistim ASA, and is located in Toronto, Ontario.

About Medistim:
Medistim was established in 1984 and has a track record of profitable growth over the past 20 years. The company is a pioneer within its segment and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark, and Norway, in addition to around 60 distributors in Europe, Asia, Middle East, Africa, Canada, and South America.
For more information, visit the Medistim home page: www.medistim.com
For more information, contact:

President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com

Kilde

[Savepig]

Jakter på higher high nå, da får vi brudd opp fra nedtrend

[TekBot]

Board approval of the 2022 Financial statements for Medistim ASA

(Oslo, 24th of March 2023) Medistim ASA (OSE: MEDI), a niche market leader
within ultrasound technology with headquarter in Norway, that develops and
commercializes medical equipment for use within cardiac, vascular and transplant
…

Vis børsmeldingen

surgery, announces that the Board of Medistim ASA has approved the Financial
Statements for 2022. The Financial Statements are without changes from the
preliminary Financial Statements published on the 1st of March 2023. The
Annual General Meeting will be held on 24th of April 2023.

Kilde

[TekBot]

Annual report for 2022 for Medistim ASA

(Oslo, 30th of March 2023) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarter in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces that the Annual Report for 2022 is approved and available.

About Medistim:
…

Vis børsmeldingen

Medistim was established in 1984, and has a track record of profitable growth over the past >15 years. The company is a pioneer within its segment, and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark, Canada and Norway, in addition to the about 60 distributors in Europe, Asia, Middle East, Africa, and South America. For more information, visit the Medistim
home page: www.Medistim.com

This information is disclosed under Norwegian law (Verdipapirhandelloven §5-12).
For more information, contact:

President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com

Kilde

[Savepig]

[tooeasy891]

CMD i opptak:

Capital Markets Day - Medistim

[TekBot]

Notice of Annual General Meeting in Medistim ASA

(Oslo, 3rd of April 2023) Medistim ASA (OSE: MEDI), a niche market leader
within ultrasound technology with headquarters in Norway, that develops and
commercializes medical equipment for use within cardiac, vascular and transplant
…

Vis børsmeldingen

surgery, announces the Annual General Meeting for the company.

The Annual General Meeting will take place on the 24th of April 2023 at 10.00
and is held at Medistim’s offices at Økernveien 94 in Oslo. Attached are the
agenda for the meeting, the voting form and the annual report for 2022. It is
possible to give proxy with and without voting instructions. By using a proxy
with voting instructions, the shareholders will vote on the specific issues
without personal attendance. For further information on the use of proxy, see
general information at the bottom of the notice and enclosed proxy forms.

Attached is also the annual report for 2022 for Medistim ASA in PDF format and
in ESEF format. The report will also be available on the company web
site: www.medistim.com.

About Medistim:

Medistim was established in 1984, and has a track record of profitable growth
over the past >15 years. The company is a pioneer within its segment, and
continues to invest in new product development. Medistim has wholly owned
subsidiaries with sales organizations in the USA, Canada, China, Germany, UK, Spain, Denmark
and Norway, in addition to the about 60 distributors in Europe, Asia, Middle
East, Africa, Canada and South America. For more information, visit the Medistim
home page: www.Medistim.com

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act (Verdipapirhandelloven).

For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com

Kilde

[TekBot]

Dividend proposal for 2022 Medistim ASA - Key information

In a meeting 28 February 2023, the Board of Directors resolved to propose for
the annual general meeting an ordinary dividend for 2022 of NOK 4.50 per share.

…

Vis børsmeldingen

Dividend amount: 4.50 per share
Declared currency: NOK
Last day including right: 24 April 2023
Ex-date: 25 April 2023
Record date: 26 April 2023
Payment date: 5 May 2023
Date of approval: 24 April 2023

This information is published in accordance with the requirements of the rules
on the continuing obligations of stock exchange listed companies.

Kilde